Open Access Open Access  Restricted Access Subscription Access

Azilsartan Medoxomil:Angiotensin Receptor Blocker in the Treatment of Hypertension


Affiliations
1 Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
 

Hypertension is an important risk factor for cardiovascular and renal disease. It's early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.

Keywords

Hypertension, Azilsartan, Angiotensin Receptor Blocker.
User
Notifications
Font Size


Abstract Views: 246

PDF Views: 124




  • Azilsartan Medoxomil:Angiotensin Receptor Blocker in the Treatment of Hypertension

Abstract Views: 246  |  PDF Views: 124

Authors

M. Sood
Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
J. K. Bajaj
Punjab Institute of Medical Sciences, Jalandhar, Punjab, India

Abstract


Hypertension is an important risk factor for cardiovascular and renal disease. It's early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.

Keywords


Hypertension, Azilsartan, Angiotensin Receptor Blocker.



DOI: https://doi.org/10.18311/ijmds%2F2013%2F86746